2023-11-07 08:47:44 ET
More on Arbutus Biopharma
- Putting Arbutus Biopharma Back In The Spotlight
- Alnylam sends Arbutus lower after FDA snub for amyloidosis drug
For further details see:
Arbutus Biopharma says its CEO William Collier will retire2023-11-07 08:47:44 ET
For further details see:
Arbutus Biopharma says its CEO William Collier will retireMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
Market:
Arbutus Biopharma Corporation Website:
Asserts Arbutus’ Share of Patent Infringement Claims Against Moderna and Pfizer/BioNTech is Potentially Worth Billions of Dollars and Preserving that Value Should be a Key Focus Calls on Arbutus to Cease Any Further Share Issuances and Plans to Vote AGAINST Proposed Share Incre...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...